Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

NOV-205

Other · developed by Cellectar Biosciences

Phase 2 Most advanced trial (none active)

CLRB Developer

1 Registered trials

What is NOV-205?

NOV-205 is a drug given as a daily subcutaneous injection at doses of 30 mg or 60 mg, for 49 or 98 days. It is studied in hepatitis C.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Infectious disease
Developer: Cellectar Biosciences, Inc. (CLRB)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT01058512	Phase 2	Hepatitis C	Completed	CLRB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatitis C

More from Cellectar Biosciences

Cyclophosphamate Phase 3 Iodine I 124 Iopofosine Phase 2 Iodine I 125 Iopofosine Phase 1 Iodine I 131 Iopofosine Phase 3 NM404 Phase 1 NOV-002 Phase 3

Sources

ClinicalTrials.gov NCT01058512

Updated Oct 11, 2026. Something wrong or missing? Report it on the CLRB page.

Follow CLRB, the company behind NOV-205

See CLRB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CLRB catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z